← brief for 2026-10-12 · Slowing decline

Characterizing the Adverse Event Profile of Semaglutide: A Comprehensive U.S. Food and Drug Administration Adverse Event Reporting System-Based Pharmacovigilance Study.

Key takeaways

This study looked at safety reports for semaglutide, a diabetes and weight loss drug. It used data from the FDA database. It shows what side effects people report, but it does not prove cause.

Who did this work

Thawkar SA · Singare SR · Sakle NS

Source

Article · PubMed, the drug frontier · 2026 Oct 12
https://pubmed.ncbi.nlm.nih.gov/42863671/